

## IPSC differentiation into ependymal progenitors to treat ventricular damage during hydrocephalus

Luis Manuel Rodriguez-Perez<sup>1,2</sup>, AJ Jiménez<sup>1,2</sup>, P Páez-González<sup>1,2</sup>

<sup>1</sup> Department of Cell Biology, Genetics, and Physiology, University of Malaga, 29071, Spain

<sup>2</sup> IBIMA, Malaga, Spain

Name of the corresponding author: **Patricia Paez-Gonzalez**

**Introduction:** During both obstructive congenital hydrocephalus and post-hemorrhagic hydrocephalus additional pathological events are intimately associated with their ethiology: a) a detrimental inflammatory response; b) severe damage of the underlying periventricular nervous tissue, including white matter, and c). Therapeutic approaches have been directed to overcome a) and b), however recovery of damaged neuroepithelium/ependyma is, in our present, an important therapeutic gap.

**Methods:** Human and mouse induced pluripotent stem cells (iPSC) have been artificially differentiated into ependymal progenitors. Intracerebroventricular (ICV) injections of iPSCs are performed ex vivo and in vivo in the damaged ventricular wall. Their integration and differentiation has been studied by immunohistochemistry and histopathological analysis.

**Results:** Mice and human ependymal progenitors are able to integrate and differentiate into ependyma in damaged ventricular wall. Stage of ependymal differentiation by the time of the injection defined different degrees of integration.

**Conclusions:** iPSC appear to be a good ependymal progenitor source with no ethical controversy associated.

**Supported by Universidad de Málaga, Andalucía Tech, and RyC 2014-16980 to PP-G.**

In submitting an abstract to the to the International Society for Hydrocephalus & Cerebrospinal Fluid Disorders I warrant, on behalf of myself and any co-authors, that either:

A)  **I, and all co-authors give our permission to publish the abstract, under the following terms:**

I am authorized by my co-authors to enter into these arrangements.

I/we agree that the abstract, if editorially accepted for publication in *Fluids and Barriers of the CNS*, shall be licensed under an open access Creative Commons Attribution License 4.0. In line with the journal's Open Data Policy, data included in the abstract shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated.

I/we agree to the following editorial requirements:

a. the abstract is original, has not been formally published in any peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third-party rights;

b. I am/we are the sole author(s) of the abstract and have full authority to grant publication rights to to the International Society for Hydrocephalus & Cerebrospinal Fluid Disorders and are not in breach of any other obligation;

c. I/we have taken due care to ensure the scientific integrity of the abstract.

d. **Consent to publish:** If the abstract is a case study or otherwise contains details relating to individual participants, such as three or more identifiable pieces of information (age, gender, diagnosis, weight, height etc.), written informed consent for the publication of these details must be obtained from the participants. A statement to this effect should appear at the end of the

abstract, e.g. "Informed consent to publish has been obtained from the patient". If the patient is deceased consent for publication should be obtained from the next of kin. If the patient is under 16, consent should be obtained from the parent or guardian. I/we warrant that that I/we understand this policy and will obtain and include a consent to publish statement where necessary, or else the abstract will not be accepted for publication.

OR

B)  I and all co-authors DO NOT give our permission to publish the abstract. I am authorized by my co-authors to enter into these arrangements.